{"id":852848,"date":"2025-05-20T09:18:11","date_gmt":"2025-05-20T13:18:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/"},"modified":"2025-05-20T09:18:11","modified_gmt":"2025-05-20T13:18:11","slug":"longeveron-to-attend-bio-international-convention-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/","title":{"rendered":"Longeveron\u00ae to Attend BIO International Convention 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Focus on potential partnership and strategic opportunities for the Company\u2019s stem cell therapy program for Alzheimer\u2019s disease<\/em>\n        <\/li>\n<li>\n          <em>Recent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2\/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer\u2019s disease<\/em>\n        <\/li>\n<li>\n          <em>Initiation of planned single, pivotal Phase 2\/3 clinical trial in mild Alzheimer\u2019s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and\/or partnering support<\/em>\n        <\/li>\n<li>\n          <em>Results from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer\u2019s disease were published in the peer reviewed journal Nature Medicine<\/em>\n        <\/li>\n<li>\n          <em>Laromestrocel is, to Company\u2019s knowledge, the first cellular therapeutic candidate to receive FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer\u2019s disease<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">MIAMI, May  20, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MLRtgIrAmsadv6OjDxZ4G98IX4znDAqimfwQCTO3bMjbMOZqLOs49HOe9Pn4btk4CznelvkKHC8aeKSGjhsvYYxRyUep7Q6BeXHAnstf_YA=\" rel=\"nofollow\" target=\"_blank\">Longeveron Inc.<\/a> (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company will participate in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uDzzAJc9b8VTFPr5cdntzt-A8CVvcr_Y6Z9pnWUFdzSLhMKyi4scXkGAnfxGYNKy9pGz4Mmc7I6IShwPdvnrgF9XK023VH5rv408ioxfk_ysDsMSuFQ74p1ajoIm-5-1\" rel=\"nofollow\" target=\"_blank\">BIO International Convention<\/a> taking place June 16-19, 2025 at the Boston Convention &amp; Exhibition Center.<\/p>\n<p align=\"justify\">At the conference, members of the Longeveron management team will host meetings with global pharmaceutical company executives to explore potential partnership and strategic opportunities for the Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n0hpjrbqiE_hDYrS2UUovH-CQkVQAOEAReMK99rruBSZlXBYJ8NxVaWrV8nDgWhRwnvlV_UhYQvC5Dg2KUdfhMd9CQIg90ZMECXfsNM4NHW5AC8Hx6vSEeIkcVy2oUukyTrzb6GcSqEztjmb_p6c-g==\" rel=\"nofollow\" target=\"_blank\">Alzheimer\u2019s disease program<\/a>, which has generated positive data in successful Phase 1 and Phase 2 clinical trials.\u00a0\u00a0 Results from the Phase 2a clinical trial (CLEAR MIND), which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer\u2019s disease, were <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iw8oSntb7GAslyRzg6NVV9Jf0ktfrC7NG4WjqeWjuIfQbLLf2lKgKIB3f1_vBcEP_m8JawJf8odo2CxRtaeBZ8O2zqEz3ELjDHXsexAftRpBP1AaEOf7GCr4VlinC2hr\" rel=\"nofollow\" target=\"_blank\">published<\/a> in the peer reviewed journal <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dWK14bomIQ_kgor1C8LBXHqcfZYN_92UWn_YvNBuIqFnhBXrKOa_t4bnhyVzohTpgWlxO_Bet-CxywW4F4ioFLsdxBMDbnNLaZSOya0HT34=\" rel=\"nofollow\" target=\"_blank\"><em>Nature Medicine<\/em><\/a> in March 2025.<\/p>\n<p align=\"justify\">Longeveron\u2019s lead investigational therapeutic candidate is <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uF2ubDAydUlFysXu0c5UzdD0Aj3bjEfj5YHToOjGXQqQkHQb7Mbnf2mCDbwNYi3N58uN7ZyIc9fZDe8LMa-CEF72G6Ebwn7HCIct73MA550=\" rel=\"nofollow\" target=\"_blank\">laromestrocel<\/a>, a proprietary, scalable, allogenic cellular therapy. In the completed Phase 2a clinical trial (CLEAR MIND), laromestrocel treated patients showed an overall slowing\/prevention of disease worsening compared to placebo. The trial achieved the primary safety and secondary efficacy endpoints and showed statistically significant improvements in pre-specified clinical and biomarker endpoints in specific laromestrocel groups compared to placebo.<br \/>\u00a0\u00a0 <br \/>Longeveron previously announced\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mhueFsGLiZhaA5s-ys3fM-LdZYhM3FctV9gIgRdw91kzpFTwWeAw1s4CqFVr92Q835Ryz3Xsx3FqQ30eXRuWsk9TJmat7uwV1FgdISIGPxHhl28O8b9PL8tUycRlUcNvs6i19Mk5eOBYhRuA6tSYwXn1y5LI9aSoHVsR73JpkJVEZS7RMpkSVsL0WU4VaIq8TyMMMj83tf0M0joXXz8S5tR6oqbSS_JIN7TrsJvACYoU0QW7DpmlZo_LLY-cP3KhDRYBe1hKQfoxafJc_1Ju-VusANUnQRNjdhHBjvLWuOzrUo6i-R7o1b6nEVzSRFl-Pr7CccPt-CEBWawVBNDo43uK18j0-XSJKHDp-CHU77pbi_mNhIz3vCIRPOVjUuB6ATN6bqbKUkSSRg18P220kPk8vs6wu8hPZO9GJtKZUNNmxZH1xhyZLi2wFKOLBqB9rOce1pc_Siw5WZFKwMG111mhVsg4_ujZnu9Uj1p780KGN6LyagUfL3D42Cw2R5kb--WQTpxiiQdRN_ExgFcTBuJtbqq4BGgZ6femRjCcSfLBtGcGUrLbKJm-2142nmaedzSNUcXspQlVG__I_cCCuaVuK3tJYRWq09gqyu7yGqY=\" rel=\"nofollow\" target=\"_blank\">top-line results<\/a>\u00a0for the CLEAR MIND Phase 2a clinical trial on October 5, 2023, and reported\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I-OA6VqSdiPsrOpGuINlNiOg-vWJMZv63alzw6VcN3MtBreyGoUbb9eXrRRvBplnSNU-h_12Gdc0I_6QzaKnPijJuDQXF0hybrAOHnO8c4RzWqbfEfsXGm1KF-pPEAZRYUV2F8J0ulQe7vcqaHSqCvSHP5BJ9NYczQ4vpsCmFefl3TXQ1MlvhAJcO6igSOWUdaaj5IuOBnDdy_0btvKGP61D-YSYUTwPxJLMZzVmQqEkS8dO_5uOq8O5Yixoiy4QHcnn1sYxM8UP5s466hWe0hRhIRQW7NaFYI9UtOFo-ZdUlL4H9rzMNvuC5eUhIshVy-fYGBP5dPCrndhuOpBhPfTQJOJKgGj3ApBnW3to3ctYZuauBRU2OzDGEO9VBKMagqBNL838-ureKeSKWSCTSiRQ-Wtb9SD373ZTwEoQBzUQ8ODlzMfUmaP_zdol9uDy6uYFtq7XzgfRt6Xim2TEIOcoqjsfLuHln0uV7zPGhogErI2U4WuObNXYvZE4x0lC4FmU7nibjJaCNQFUa6PbfjujygUfNwsqkG3t4_Fn1GWPeC_mftvvd_vZ7oECl7-1wACPBZJ8Wg8c1JPIRiuWZyShL56qQWMWVbM2fks5vYVh8wV1XpFnYpU672f6JnyJOLPgPOBo5trS2j4m51ul6OyMX8E19hoayk5771tQnnabve5LtFF-wXMFHPaD7CX-XYFIUavrWTd_Pu3pjAKCTEkXm0Gk__1Suip-KAUqEp7PkS9pdjTWZnDJdNWRldG-\" rel=\"nofollow\" target=\"_blank\">additional clinical data and imaging biomarker results<\/a>\u00a0from CLEAR MIND on December 20, 2023. Full results from the CLEAR MIND study were presented in a featured research oral presentation at the 2024 Alzheimer&#8217;s Association International Conference (AAIC).<\/p>\n<p align=\"justify\">The FDA has granted laromestrocel both <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8HxH8faVIeQ6iaLY177qGTZwa2OIMOkrkbkKf5HErimG3z4p8kDVEn2kc4Fgpc3XvBfxT4UQDBB9Zx0wt1tQJ5A9sjIjRhOS4cdLTYnBPSKDniSdLICe-WAUgAzrJM8GlspNOhyhYpIIMzSackEBsBGK_dJDcB79n2Dm56_ghsyB5G8R0kUrH7R_QJv25PjrFcGzp_Kkj1xmn47j3asfHfABTLhQLNX6JEoxVMgD52xJ8waRj69Aw3AyBiFYPe2X1alQd916n7dI7RKw6hgZrQ==\" rel=\"nofollow\" target=\"_blank\"><u>Regenerative Medicine Advanced Therapy (RMAT)<\/u><\/a>\u00a0designation and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NulDSIglWuE9r66B1K5KQ5aSJKcGMaJXDgc3_w5sCevTMAQ4DyHyKPBG9qkE9-ff0Kqek-RSZRDkIhfqkuWe-PZc3MfjSMy6mNtIKnpMOM31-6FJ7WacbXv6X-EKyEem8_SNcV4EWZqAjnxM7FhipFM3Ar1FJfXxjfk5WmoR_jmUqu0vlSTED_4uxCp1ZavjQCPnHE9TtWRJkDtxw8H1TA==\" rel=\"nofollow\" target=\"_blank\"><u>Fast Track<\/u><\/a> designation for the treatment of mild Alzheimer\u2019s disease, which allow greater access to FDA interaction during laromestrocel\u2019s development for Alzheimer\u2019s disease. Laromestrocel is, to Company\u2019s knowledge, the first cellular therapeutic candidate to receive FDA RMAT designation for Alzheimer\u2019s disease.<\/p>\n<p align=\"justify\">To connect with Longeveron during the conference, please request a meeting via the BIO International Conference meeting portal or contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XZ0n2h0PR1fVQRgQ08yfVpycgi-JYGM2HAElKhgHG-2PlihE52l4-a8ZVx14x-zZcVE-qyw_0aE8wyX8-gqDdWjO6ZZI7NLRYybjkmNWWtE=\" rel=\"nofollow\" target=\"_blank\">info@longeveron.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Longeveron Inc<\/strong><br \/>\n        <strong>.<br \/><\/strong>Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s lead investigational product is laromestorcel, an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer\u2019s disease, and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program &#8211; Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program &#8211; Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9xP_2pTjQHIKpGyhqRWJJGR1JLJeDNrWxat6ts0xXD6yXQwroJ7l_xpUdcXZ8_UVEps73Nso9kxixZySsjcZUTFRnAhXZBsEqN4gtdDA2Hw=\" rel=\"nofollow\" target=\"_blank\"><u>www.longeveron.com<\/u><\/a> or follow Longeveron on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V4UUlGc_V8U6H4pTtHQ80p0YpHbXGRiYgNrb6s1rIfgMOh9H2vsxgIwPTJetxbIMfkeIXgzhMQq0WrB8_eX1JyK6Fp-ftXC4zFspQmbLoAPZCjJ8_Nmlx2R9mSLP64Oq\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yz8P9Pzqq0Cb_lXM4xH2XfUFnJn1pR7KOVpB184rfgQjV9IHj6iZ_toat0HJeYRLCtZ_VhPZZikEFOpoZQTQtA==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l1adr4koBCzLCwevf50_1wlujhBab8rnKGK6SqRlpNFeBi459KWgT58tPO2Na6tLnktCwpHQfFjcbxuS4FgLp-HGL1lPowItgdvbiucvtqk=\" rel=\"nofollow\" target=\"_blank\"><u>Instagram<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management\u2019s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpects,\u201d \u201cintend,\u201d \u201clooks to,\u201d \u201cmay,\u201d \u201con condition,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cpreliminary,\u201d \u201cproject,\u201d \u201csee,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects and include, but are not limited to, statements about the various below-listed factors. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.<\/p>\n<p align=\"justify\">Further information relating to factors that may impact the Company\u2019s results and forward-looking statements are disclosed in the Company\u2019s filings with the Securities and Exchange Commission, including Longeveron\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company\u2019s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Derek Cole<br \/>Investor Relations Advisory Solutions<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pXTkUwetFSmT2Ue6QTc1Gdw_ozzd1F5qU4fyL06Sv-VBDAglKw1-h6I4fqznCK-vYBmnhNTKd5EzSBS2MyCKqwrWbN83wmpNiTpYy39J_pcgClwCSxfsU_lWjdQwYDWo\" rel=\"nofollow\" target=\"_blank\"><u>derek.cole@iradvisory.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWQxODExMDYtMmRjMC00NGNkLWEzMDgtYmZkMGQ1ODI2YjBmLTEyMTg2MTMtMjAyNS0wNS0yMC1lbg==\/tiny\/Longeveron.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Focus on potential partnership and strategic opportunities for the Company\u2019s stem cell therapy program for Alzheimer\u2019s disease Recent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2\/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer\u2019s disease Initiation of planned single, pivotal Phase 2\/3 clinical trial in mild Alzheimer\u2019s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and\/or partnering support Results from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer\u2019s disease were published in the peer reviewed journal Nature Medicine Laromestrocel is, to Company\u2019s knowledge, the first cellular therapeutic candidate to receive FDA Regenerative Medicine Advanced Therapy (RMAT) designation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Longeveron\u00ae to Attend BIO International Convention 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-852848","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Longeveron\u00ae to Attend BIO International Convention 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longeveron\u00ae to Attend BIO International Convention 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Focus on potential partnership and strategic opportunities for the Company\u2019s stem cell therapy program for Alzheimer\u2019s disease Recent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2\/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer\u2019s disease Initiation of planned single, pivotal Phase 2\/3 clinical trial in mild Alzheimer\u2019s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and\/or partnering support Results from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer\u2019s disease were published in the peer reviewed journal Nature Medicine Laromestrocel is, to Company\u2019s knowledge, the first cellular therapeutic candidate to receive FDA Regenerative Medicine Advanced Therapy (RMAT) designation &hellip; Continue reading &quot;Longeveron\u00ae to Attend BIO International Convention 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T13:18:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longeveron\u00ae to Attend BIO International Convention 2025\",\"datePublished\":\"2025-05-20T13:18:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/\"},\"wordCount\":1258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/\",\"name\":\"Longeveron\u00ae to Attend BIO International Convention 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=\",\"datePublished\":\"2025-05-20T13:18:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-to-attend-bio-international-convention-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longeveron\u00ae to Attend BIO International Convention 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longeveron\u00ae to Attend BIO International Convention 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/","og_locale":"en_US","og_type":"article","og_title":"Longeveron\u00ae to Attend BIO International Convention 2025 - Market Newsdesk","og_description":"Focus on potential partnership and strategic opportunities for the Company\u2019s stem cell therapy program for Alzheimer\u2019s disease Recent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2\/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer\u2019s disease Initiation of planned single, pivotal Phase 2\/3 clinical trial in mild Alzheimer\u2019s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and\/or partnering support Results from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer\u2019s disease were published in the peer reviewed journal Nature Medicine Laromestrocel is, to Company\u2019s knowledge, the first cellular therapeutic candidate to receive FDA Regenerative Medicine Advanced Therapy (RMAT) designation &hellip; Continue reading \"Longeveron\u00ae to Attend BIO International Convention 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-20T13:18:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longeveron\u00ae to Attend BIO International Convention 2025","datePublished":"2025-05-20T13:18:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/"},"wordCount":1258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/","name":"Longeveron\u00ae to Attend BIO International Convention 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=","datePublished":"2025-05-20T13:18:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDI0OSM2OTQ5NTA2IzIyMDcwNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-to-attend-bio-international-convention-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longeveron\u00ae to Attend BIO International Convention 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=852848"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852848\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=852848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=852848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=852848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}